Fatemeh Chaharlang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fatemeh Chaharlang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Ahmadi
Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
1 shared publication - Mohammad Khalaj-Kondori
Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
1 shared publication Nafiseh Mahdipour
Department of Biotechnology, Faculty of Biological Sciences, Islamic Azad University of Falavarjan, Isfahan, Iran
1 shared publicationParichehr Angouti
Department of Biological Sciences, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan, Iran
1 shared publication- Sana Alizadeh Rami
Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
1 shared publication
Latest Publications
- 1 June 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (6) , 758-774
Target therapeutic exploitation of engineered exosome-mediated delivery of ncRNAs in cancer
Non-coding RNAs, as microRNAs, long non-coding RNAs, and circular RNAs, are significant modulators of tumor biology and gene expression. miRNAs primarily regulate gene expression at the post-transcriptional level, whereas lncRNAs influence transcriptional activity and epigenetic states. Moreover, circRNAs function as highly stable molecules that shape oncogenic pathways by sequestering miRNAs and interacting with RNA-binding proteins. By addressing these regulatory roles, ncRNAs have emerged as attractive candidates for therapeutic intervention, yet their clinical translation remains limited by rapid degradation, insufficient cellular uptake, and off-target effects. Engineered exosomes—natural nanosized vesicles with strong biocompatibility and barrier-crossing capacity—represent a promising platform to overcome these delivery challenges. This review provides a comprehensive overview of recent advances in exosome engineering for cancer-directed ncRNA delivery. We summarize state-of-the-art strategies designed to enhance loading efficiency, targeting specificity, and therapeutic performance of exosome-mediated delivery systems for miRNAs, lncRNAs, and circRNAs, and outline their growing potential in next-generation cancer therapy.
- 1 June 2026
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (6) , 758-774
Target therapeutic exploitation of engineered exosome-mediated delivery of ncRNAs in cancer
Non-coding RNAs, as microRNAs, long non-coding RNAs, and circular RNAs, are significant modulators of tumor biology and gene expression. miRNAs primarily regulate gene expression at the post-transcriptional level, whereas lncRNAs influence transcriptional activity and epigenetic states. Moreover, circRNAs function as highly stable molecules that shape oncogenic pathways by sequestering miRNAs and interacting with RNA-binding proteins. By addressing these regulatory roles, ncRNAs have emerged as attractive candidates for therapeutic intervention, yet their clinical translation remains limited by rapid degradation, insufficient cellular uptake, and off-target effects. Engineered exosomes—natural nanosized vesicles with strong biocompatibility and barrier-crossing capacity—represent a promising platform to overcome these delivery challenges. This review provides a comprehensive overview of recent advances in exosome engineering for cancer-directed ncRNA delivery. We summarize state-of-the-art strategies designed to enhance loading efficiency, targeting specificity, and therapeutic performance of exosome-mediated delivery systems for miRNAs, lncRNAs, and circRNAs, and outline their growing potential in next-generation cancer therapy.